Delayed growth of EL4 lymphoma in SR-A-deficient mice is due to upregulation of nitric oxide and interferon-γ production by tumor-associated macrophages

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2160-2166

  Komohara, Yoshihiro ^a   Takemura, Kenichi ^a   Lei, Xiao Feng ^a   Sakashita, Naomi ^a   Harada, Mamoru ^b   Suzuki, Hiroshi ^c   Kodama, Tatsuhiko ^d   Takeya, Motohiro ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; MESSENGER RNA; NITRIC OXIDE; SCAVENGER RECEPTOR A; TOLL LIKE RECEPTOR 4;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; GROWTH INHIBITION; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; UPREGULATION; WILD TYPE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CYTOKINES; INTERFERON-GAMMA; LYMPHOMA; MACROPHAGES; MICE; MICE, INBRED C57BL; NITRIC OXIDE; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS A; UP-REGULATION;

EID: 71049140879     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01296.x     Document Type: Article

References (37)

1. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-8.
2. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-55.
3. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
4. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-12.
5. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-86.
6. Platt N, Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional? The mouse's tale. J Clin Invest 2001, 108:649-54.
7. Suzuki H, Kurihara Y, Takeya M. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386:292-6.
8. Matsumoto A, Naito M, Itakura H. Human macrophage scavenger receptors: primary structure, expression, and localization in atherosclerotic lesions. Proc Natl Acad Sci USA 1990, 87:9133-7.
9. Yang G, Addai J, Tian WH, Frolov A, Wheeler TM, Thompson TC. Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res 2004, 64:2076-82.
10. Hagemann T, Wilson J, Burke F. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006, 176:5023-32.
11. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008, 216:15-24.
12. Haworth R, Platt N, Keshav S. The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock. J Exp Med 1997, 186:1431-9.
13. Kobayashi H, Sakashita N, Okuma T. Class A scavenger receptor (CD204) attenuates hyperoxia-induced lung injury by reducing oxidative stress. J Pathol 2007, 212:38-46.
14. Tsujita K, Kaikita K, Hayasaki T. Targeted deletion of class A macrophage scavenger receptor increases the risk of cardiac rupture after experimental myocardial infarction. Circulation 2007, 115:1904-11.
15. Seimon TA, Obstfeld A, Moore KJ, Golenbock DT, Tabas I. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci USA 2006, 103:19794-9.
16. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008, 20:518-23.
17. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008, 68:4026-30.
18. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008, 180:5067-74.
19. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-35.
20. Kamada N, Kodama T, Suzuki H. Macrophage scavenger receptor (SR-A I/II) deficiency reduced diet-induced atherosclerosis in C57BL/6J mice. J Atheroscler Thromb 2001, 8:1-6.
21. Komohara Y, Terasaki Y, Kaikita K, Suzuki H, Kodama T, Takeya M. Clearance of apoptotic cells is not impaired in mouse embryos deficient in class A scavenger receptor types I and II (CD204). Dev Dyn 2005, 232:67-74.
22. Bonnem EM, Oldham RK. Gamma-interferon: physiology and speculation on its role in medicine. J Biol Response Mod 1987, 6:275-301.
23. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984, 2:336-52.
24. Maekawa R, Kitagawa T, Hojo K, Wada T, Sato K. Distinct antitumor mechanisms of recombinant murine interferon-gamma against two murine tumor models. J Interferon Res 1988, 8:227-39.
25. Platt N, da Silva RP, Gordon S. Class A scavenger receptors and the phagocytosis of apoptotic cells. Immunol Lett 1999, 65:15-9.
26. Platt N, Suzuki H, Kurihara Y, Kodama T, Gordon S. Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro. Proc Natl Acad Sci USA 1996, 93:12456-60.
27. Platt N, Suzuki H, Kodama T, Gordon S. Apoptotic thymocyte clearance in scavenger receptor class A-deficient mice is apparently normal. J Immunol 2000, 164:4861-7.
28. Jacobs AT, Ignarro LJ. Lipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW 264.7 macrophages. J Biol Chem 2001, 276:47950-7.
29. Komohara Y, Hirahara J, Horikawa T. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006, 54:763-71.
30. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-11.
31. Gresser I. Antitumor effects of interferon. Acta Oncol 1989, 28:347-53.
32. Xie K, Dong Z, Fidler IJ. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol 1996, 59:797-803.
33. Thomsen LL, Miles DW. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 1998, 17:107-18.
34. Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 1994, 54:2462-7.
35. Martin JH, Edwards SW. Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. Reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas reactive nitrogen intermediates are employed by macrophages in tumor cell killing. J Immunol 1993, 150:3478-86.
36. Hagemann T, Lawrence T, McNeish I. " Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008, 205:1261-8.
37. Ryoyama K. Effector molecules from antitumor macrophages induced with OK-432 and cyclophosphamide. Cancer Immunol Immunother 1992, 35:7-13.